Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent oral poliovirus vaccine (Beijing Institute of Biological Products)
- Development stage
- Unknown
- Lead developer
- Beijing Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
The BBIBP Bivalent Oral Poliomyelitis Vaccine (BBIBP bOPV) is a live attenuated oral vaccine developed by Beijing Bio-Institute Biological Products (BBIBP) in collaboration with PATH. It contains a suspension of attenuated poliovirus Sabin strains of types 1 and 3. The vaccine is indicated for active immunization against poliomyelitis caused by these specific types, primarily for use in routine immunization and supplementary immunization activities (SIAs) in children. It received WHO prequalification following a Phase 3 clinical trial in Kenya, which demonstrated its safety and immunogenicity compared to existing WHO-prequalified bOPVs. The vaccine is intended to help meet global demand for bOPV, particularly in polio-endemic and high-risk low-income countries.
- Brand names
- Beijing TiantanBio Liquid Bivalent Oral Poliomyelitis Vaccine
- Other names
- BBIBP Bivalent Oral Poliomyelitis VaccineBeijing TiantanBio Liquid Bivalent Oral Poliomyelitis VaccinebOPV
Beyond the preview
Go deeper on bivalent oral poliovirus vaccine (Beijing Institute of Biological Products).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent oral poliovirus vaccine (Beijing Institute of Biological Products).